This document discusses strategies for investigating and prosecuting prescription drug cases. It provides an overview of how investigations are initiated, such as through complaints or reports of patient deaths. The presentation then covers investigative resources like medical records, pharmacy records, autopsy reports, toxicology results, witness interviews, and undercover operations. Details are given on obtaining search warrants, collecting evidence at clinics and storage facilities, and seizing financial records. The objectives are to identify challenges in Rx drug investigations, understand possible charges, and explain prosecuting cases against medical professionals.
Web only rx16 len wed_1230_1_daugherty_2baier-haasOPUNITE
This document summarizes a presentation on investigating and prosecuting drug-related homicides. It discusses signs that can indicate an overdose death, such as the presence of drugs, track marks, and foam coming from the mouth. It emphasizes treating the death scene like a homicide scene by thoroughly photographing and collecting all potential evidence. This includes searching for drug packaging, needles, phones and surveillance footage. The document also outlines interviewing witnesses to build a timeline and identify the victim's source of drugs. It suggests attempting a controlled buy from suspects to obtain contemporaneous drug samples and strengthen cases.
1. Co-prescribing opioids and benzodiazepines poses serious health risks like respiratory depression and increased risk of overdose death. Delaware has high rates of prescriptions for these drugs.
2. Delaware's PDMP collects prescription data that can help identify patients and providers with troubling patterns of co-prescribing to reduce risks. Regular screening and urine tests can also help address misuse.
3. PDMP data analysis found that in 2013 over 12% of individuals in Delaware filled prescriptions for both drug classes, putting them at risk. The PDMP is a valuable tool to improve prescribing practices and detect misuse.
The origins of the current heroin crisis in America can be traced back to the overprescription of opioid painkillers in recent decades. As opioid prescriptions and sales increased aggressively starting in the late 1990s, so too did rates of opioid addiction, overdose deaths, and users transitioning from prescription opioids to heroin. While heroin use has been an issue in the past as well, linked to wars and social movements, the current crisis is uniquely tied to changes in opioid prescribing practices that flooded the country with highly addictive pain pills and helped reintroduce heroin as a cheaper alternative to prescription opioids.
The document summarizes a Heroin Response Strategy presented by experts from various High Intensity Drug Trafficking Areas. The strategy involves 3 components: 1) Establishing a regional public health and public safety information sharing network through "Points of Light" teams in each state. 2) Implementing community education and prevention programs. 3) Creating a platform for regional public health and public safety partnerships through annual symposiums. The goal is to reduce drug overdoses through enhanced collaboration between law enforcement and health agencies.
This document discusses drug court models and the role of law enforcement in drug courts. It begins with introductions from presenters and outlines learning objectives about explaining drug court operations and benefits, how law enforcement can utilize drug courts, and identifying best practices. The following sections provide details on drug court models, including how they integrate treatment into the justice system using a non-adversarial approach. Key components of drug courts are outlined, and presenters discuss issues like prescription drug and heroin abuse as well as outcomes from drug courts in reducing recidivism and saving money. Law enforcement can play roles in prevention, addressing domestic violence, and targeting the right populations for drug court involvement through assessment.
This document discusses strategies for reducing buprenorphine diversion and pill mills while improving access to treatment. It notes that limiting access to buprenorphine treatment is associated with increased diversion, while expanded access to quality treatment decreases diversion and overdose deaths. The document recommends educating prescribers, using medically-derived prescribing standards, ensuring adequate insurance coverage of safe prescribing practices, and addressing diversion risks for other controlled medications. It argues against onerous new regulations that could limit treatment access. The goal is to identify and support high-quality treatment while prosecuting criminal operations.
Web only rx16 len-tues_330_1_kougasian-sakacs_2niedermannOPUNITE
Three prosecutors presented on investigating and prosecuting homicide by a prescribing doctor. They discussed two criminal cases that resulted in convictions, including a case in New York where a doctor was convicted of manslaughter and reckless endangerment for overprescribing opioids. They identified challenges in investigating doctor-caused deaths and how they prepared evidence showing the doctor's conduct grossly deviated from medical standards. A prosecutor from Los Angeles then discussed prosecuting a doctor for murder based on killings that occurred during the felony of over-prescribing controlled substances. Undercover operations and search warrants provided evidence of the doctor's conduct.
This document summarizes a presentation on state and federal responses to the opioid epidemic. It discusses innovations from the Kentucky Attorney General including legislative measures targeting pill mills and heroin, programs to expand treatment and recovery, and education initiatives. It also describes the federal response through the Organized Crime Drug Enforcement Task Force (OCDETF), including their national heroin initiative targeting criminal organizations trafficking illegal opioids and heroin, and partnerships with other agencies to address public health and public safety aspects of the epidemic. The presentation outlines strategies at both state and federal levels aimed at improving access to treatment while also enforcing penalties on dealers through investigation and prosecution efforts.
Web only rx16 len wed_1230_1_daugherty_2baier-haasOPUNITE
This document summarizes a presentation on investigating and prosecuting drug-related homicides. It discusses signs that can indicate an overdose death, such as the presence of drugs, track marks, and foam coming from the mouth. It emphasizes treating the death scene like a homicide scene by thoroughly photographing and collecting all potential evidence. This includes searching for drug packaging, needles, phones and surveillance footage. The document also outlines interviewing witnesses to build a timeline and identify the victim's source of drugs. It suggests attempting a controlled buy from suspects to obtain contemporaneous drug samples and strengthen cases.
1. Co-prescribing opioids and benzodiazepines poses serious health risks like respiratory depression and increased risk of overdose death. Delaware has high rates of prescriptions for these drugs.
2. Delaware's PDMP collects prescription data that can help identify patients and providers with troubling patterns of co-prescribing to reduce risks. Regular screening and urine tests can also help address misuse.
3. PDMP data analysis found that in 2013 over 12% of individuals in Delaware filled prescriptions for both drug classes, putting them at risk. The PDMP is a valuable tool to improve prescribing practices and detect misuse.
The origins of the current heroin crisis in America can be traced back to the overprescription of opioid painkillers in recent decades. As opioid prescriptions and sales increased aggressively starting in the late 1990s, so too did rates of opioid addiction, overdose deaths, and users transitioning from prescription opioids to heroin. While heroin use has been an issue in the past as well, linked to wars and social movements, the current crisis is uniquely tied to changes in opioid prescribing practices that flooded the country with highly addictive pain pills and helped reintroduce heroin as a cheaper alternative to prescription opioids.
The document summarizes a Heroin Response Strategy presented by experts from various High Intensity Drug Trafficking Areas. The strategy involves 3 components: 1) Establishing a regional public health and public safety information sharing network through "Points of Light" teams in each state. 2) Implementing community education and prevention programs. 3) Creating a platform for regional public health and public safety partnerships through annual symposiums. The goal is to reduce drug overdoses through enhanced collaboration between law enforcement and health agencies.
This document discusses drug court models and the role of law enforcement in drug courts. It begins with introductions from presenters and outlines learning objectives about explaining drug court operations and benefits, how law enforcement can utilize drug courts, and identifying best practices. The following sections provide details on drug court models, including how they integrate treatment into the justice system using a non-adversarial approach. Key components of drug courts are outlined, and presenters discuss issues like prescription drug and heroin abuse as well as outcomes from drug courts in reducing recidivism and saving money. Law enforcement can play roles in prevention, addressing domestic violence, and targeting the right populations for drug court involvement through assessment.
This document discusses strategies for reducing buprenorphine diversion and pill mills while improving access to treatment. It notes that limiting access to buprenorphine treatment is associated with increased diversion, while expanded access to quality treatment decreases diversion and overdose deaths. The document recommends educating prescribers, using medically-derived prescribing standards, ensuring adequate insurance coverage of safe prescribing practices, and addressing diversion risks for other controlled medications. It argues against onerous new regulations that could limit treatment access. The goal is to identify and support high-quality treatment while prosecuting criminal operations.
Web only rx16 len-tues_330_1_kougasian-sakacs_2niedermannOPUNITE
Three prosecutors presented on investigating and prosecuting homicide by a prescribing doctor. They discussed two criminal cases that resulted in convictions, including a case in New York where a doctor was convicted of manslaughter and reckless endangerment for overprescribing opioids. They identified challenges in investigating doctor-caused deaths and how they prepared evidence showing the doctor's conduct grossly deviated from medical standards. A prosecutor from Los Angeles then discussed prosecuting a doctor for murder based on killings that occurred during the felony of over-prescribing controlled substances. Undercover operations and search warrants provided evidence of the doctor's conduct.
This document summarizes a presentation on state and federal responses to the opioid epidemic. It discusses innovations from the Kentucky Attorney General including legislative measures targeting pill mills and heroin, programs to expand treatment and recovery, and education initiatives. It also describes the federal response through the Organized Crime Drug Enforcement Task Force (OCDETF), including their national heroin initiative targeting criminal organizations trafficking illegal opioids and heroin, and partnerships with other agencies to address public health and public safety aspects of the epidemic. The presentation outlines strategies at both state and federal levels aimed at improving access to treatment while also enforcing penalties on dealers through investigation and prosecution efforts.
This document summarizes presentations from two communities - Huntington, WV and Camden County, NJ - on their responses to heroin crises. It outlines programs implemented in Huntington, including a harm reduction program, centralized information system, and drug court expansion. It also discusses the region's history with prescription drug abuse and rise in heroin and associated issues like hepatitis and neonatal abstinence syndrome. Long-term strategies proposed include expanding treatment services, promoting career opportunities for those in recovery, and preventing relapse through environmental design changes.
The document discusses factors that can lead to transition from misuse of prescription opioid analgesics to heroin initiation. Through qualitative interviews with 31 individuals in New York City, four key factors were identified: 1) Use of high dose opioid analgesics; 2) Intranasal route of administration; 3) Development of physical opioid dependence; and 4) Dissolution of stigma regarding heroin in social networks. The trajectory toward heroin use was found to be similar regardless of whether opioid analgesic initiation was recreational or medical in nature.
This document summarizes presentations from public health officials in North Carolina and Northern Kentucky on community responses to the heroin epidemic. Key points include:
- Officials from North Carolina and Northern Kentucky outlined programs and partnerships implemented in their regions to address rising rates of opioid and heroin abuse, including treatment programs, harm reduction strategies, legislation, and education initiatives.
- Data presented showed increasing rates of overdose deaths, neonatal abstinence syndrome, and infectious diseases associated with intravenous drug use such as hepatitis C in Northern Kentucky.
- Community leaders and advocates in Northern Kentucky have worked to raise awareness, pass legislation to expand access to treatment, and establish prevention and support networks to address the heroin epidemic impacting the region.
This document provides a summary of a presentation on the risks of medical marijuana and marijuana legalization. It begins with disclosures from the presenters and outlines six learning objectives. It then discusses concerns that marijuana is addictive, especially for those who start using it early, and impacts adolescent brain development. The document notes the lack of evidence that marijuana is effective for the conditions it is claimed to treat. It also discusses the risks of increased diversion of marijuana to youth and greater social acceptance of marijuana use negatively impacting public health. The document concludes with messages on how to discuss these issues with the public.
This document provides information about an advocacy track presentation on advocating for change related to addiction issues. The presentation features Gary Mendell, founder and CEO of Shatterproof, and Kim Manlove from the Indiana Addictions Issues Coalition. They will discuss strategies for influencing legislation and how people in recovery can become advocates. The learning objectives focus on advocating for state laws on PDMP usage, explaining strategies to influence legislation, describing how people in recovery can advocate, and providing counsel as part of a treatment team. The presentation then provides details on Shatterproof's story, the overdose epidemic, solutions for different populations, and legislative accomplishments in various states related to expanding access to naloxone and mandating PDMP usage.
View only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdevaOPUNITE
This document summarizes a presentation on preventing hepatitis C and HIV outbreaks. It includes learning objectives about informing attendees of risks of infectious disease outbreaks related to injection drug use and describing collaborations between injury and infectious disease programs. The presentation features four speakers from Indiana and North Carolina public health departments and focuses on lessons learned from an HIV outbreak in Indiana linked to injection drug use.
This document summarizes a presentation on closing treatment gaps in the health care and criminal justice systems for opioid use disorders. It introduces the presenters and moderator and provides learning objectives focused on improving identification and treatment of opioid use disorders in health care settings and strategies for improving outcomes for frequently incarcerated individuals. Disclosures are provided for the presenters stating that they have no relevant financial relationships.
Rx16 prev wed_330_workplace issues and strategiesOPUNITE
This document discusses workplace issues related to prescription drug abuse and strategies for prevention. It begins with introductions of the presenters and moderators. The learning objectives are then outlined as understanding challenges of prescription drug abuse in the workplace, identifying prevention strategies, and describing programs available through SAMHSA. The document then covers topics such as the scope of prescription drug misuse among workers, risks to the workplace, prevention strategies employers can consider, and available resources from SAMHSA.
This document summarizes a presentation on managing morphine equivalent dose (MED) and identifying high-risk opioid use through "red flagging." It discusses how calculating MED at the point of sale can help identify unsafe dosages and decrease opioid prescriptions. It also evaluates different methods to screen for overdose risk, finding that simple opioid use thresholds to flag patients may not accurately target those most likely to experience preventable overdoses. The presentation aims to explain MED management, describe payer solutions that reduced opioid use, and identify more precise ways to intervene with highest-risk patients.
This document summarizes a presentation on drugs to watch including tramadol, hydrocodone, and naloxone. It includes:
- Disclosures from presenters declaring no conflicts of interest.
- Learning objectives focused on analyzing the impact of schedule changes for tramadol and hydrocodone, educating on tramadol dangers, and evaluating pharmacist perspectives on naloxone.
- Information presented on the drugs including their classifications, potencies, risks of abuse and addiction, and impacts of rescheduling hydrocodone and tramadol in California. Data showed decreased hydrocodone prescriptions but increased tramadol and overall opioid prescriptions, as well as increased over
Rx16 federal tues_200_1_gladden_2halpin_3greenOPUNITE
This document provides information about the emerging fentanyl overdose epidemic in the United States from the national and state perspectives. It discusses the rise in fentanyl-related overdoses and seizures from 2013-2014 according to data from various sources. The learning objectives are to explain the epidemiology of the rise in fentanyl overdoses, identify lessons from an Ohio investigation, and describe one state's experience. Recommendations include improving detection of fentanyl through testing and surveillance, expanding naloxone access, and long-term efforts to reduce opioid overdoses through prescribing guidelines and treatment expansion.
This document summarizes a presentation on health plan involvement in safe prescribing. It includes:
1) Presentations from medical experts on prescription drug abuse trends from medical examiner data and a tribal health system's safe prescribing program.
2) A discussion of health plan policies to reduce "red flag" medication combinations like opioids plus benzodiazepines through prior authorization, formulary changes, and provider restrictions.
3) Examples of one health plan's implementation of policies like restricting methadone prescriptions to pain specialists and removing carisoprodol from its formulary.
This document summarizes a presentation on medication-assisted treatment for opioid addiction. It discusses the history of treatment approaches, including the development of methadone and buprenorphine maintenance therapies. Studies show that agonist therapies like methadone and buprenorphine are more effective at retaining patients in treatment and reducing illicit opioid use than non-medication approaches. While both methadone and buprenorphine are effective, buprenorphine has a safer side effect profile but its effectiveness may be limited by lower monitoring and adherence compared to methadone treatment. The document reviews several studies demonstrating the benefits of long-term agonist therapy over detoxification or short-term medication approaches for opioid
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanOPUNITE
This document outlines an advocacy track presentation on activating communities to address prescription drug abuse. It provides biographies of the presenters and moderators and discloses any conflicts of interest. The learning objectives are to identify best practices for implementing CADCA's seven strategies for community change to impact prescription drug issues. It then provides examples of how various coalitions across the country are utilizing each of the seven strategies, such as providing education, enhancing skills, supporting communities, and changing policies.
The panel discussed two youth prevention programs - the Give Me a Reason voluntary drug testing program for parents and the This Is (Not) about Drugs prevention program implemented in schools. The Give Me a Reason program provides free at-home drug testing kits for parents to help prevent drug use among youth. The This Is (Not) about Drugs program uses a film and lesson plan to educate students about the risks of prescription opioid and heroin use with the goal of preventing first-time drug use.
This document summarizes a presentation on advances in treating chronic pain and addiction. It includes:
- Presenters from PRIUM, American Airlines, and the Treatment Research Institute
- Learning objectives around chronic pain, psychosocial issues, Medicaid requirements for the ASAM Criteria, and implementing the criteria
- Disclosures from presenters about relevant relationships
- Overview of topics like the bidirectional relationship between physical and mental health, impacts of adverse childhood experiences, and the influence of stigma on substance use treatment
- American Airlines' workers compensation program which saw a 40% reduction in claims and lower pharmacy costs and disability after redesigning their approach to focus on early intervention and additional resources for employees with chronic
Dr. Tom Frieden, Director of the Centers for Disease Control and Prevention, keynote presentation at the National Rx Drug Abuse & Heroin Summit on March 30, 2016.
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebranOPUNITE
This document summarizes a presentation on a study examining how prescriber registration and use of a prescription drug monitoring program (PDMP) in Oregon impacted opioid prescribing patterns and patient outcomes. The study found that statewide opioid prescribing generally decreased over time, but prescribers who registered for the PDMP prescribed more after registering, especially those who used the PDMP most frequently. In contrast, prescribers who did not register prescribed less. Patients whose providers were all registered had lower overdose rates than those with some registered and some non-registered providers. The conclusions were that PDMPs may need refinements like mandatory use to optimize their impact on prescribing and outcomes.
This document summarizes findings from interviews conducted as part of a study evaluating a chronic pain management pilot program for Medicaid patients in Rhode Island. Key findings include:
1) Patients reported that complementary and alternative therapies like acupuncture, massage and chiropractic care helped them better understand the relationship between stress and pain and provided an opportunity to build trusting relationships with providers.
2) Providers noted that the program allowed patients to receive hands-on care and personal connections that they may not receive otherwise due to lack of trust in the medical system and limited therapeutic relationships.
3) The program addressed transportation barriers by having some providers conduct home visits, improving access to care for patients with mobility issues.
4)
This document provides guidelines for handling referrals of sexual assault victims at the Accident and Emergency department of GTB hospital in Delhi, India. It states that female victims will be referred to the Gynecology and Obstetrics department for further management, while male victims will be treated in the main casualty area. It outlines procedures for consent, confidentiality, evidence collection and preservation, and duties of medical practitioners for such cases. It provides steps for specific cases like rape, including informing police, examination procedures, sample collection and preservation, and issuing medical certificates.
Medical Legal Aspects and Concerns of the Mid-Level PratcionerBernard Racey
Brief look at the legal aspects and concerns facing mid-level practioners (Physician Assistants and Nurse Practioners) in the United States Heath Care Systems
This document summarizes presentations from two communities - Huntington, WV and Camden County, NJ - on their responses to heroin crises. It outlines programs implemented in Huntington, including a harm reduction program, centralized information system, and drug court expansion. It also discusses the region's history with prescription drug abuse and rise in heroin and associated issues like hepatitis and neonatal abstinence syndrome. Long-term strategies proposed include expanding treatment services, promoting career opportunities for those in recovery, and preventing relapse through environmental design changes.
The document discusses factors that can lead to transition from misuse of prescription opioid analgesics to heroin initiation. Through qualitative interviews with 31 individuals in New York City, four key factors were identified: 1) Use of high dose opioid analgesics; 2) Intranasal route of administration; 3) Development of physical opioid dependence; and 4) Dissolution of stigma regarding heroin in social networks. The trajectory toward heroin use was found to be similar regardless of whether opioid analgesic initiation was recreational or medical in nature.
This document summarizes presentations from public health officials in North Carolina and Northern Kentucky on community responses to the heroin epidemic. Key points include:
- Officials from North Carolina and Northern Kentucky outlined programs and partnerships implemented in their regions to address rising rates of opioid and heroin abuse, including treatment programs, harm reduction strategies, legislation, and education initiatives.
- Data presented showed increasing rates of overdose deaths, neonatal abstinence syndrome, and infectious diseases associated with intravenous drug use such as hepatitis C in Northern Kentucky.
- Community leaders and advocates in Northern Kentucky have worked to raise awareness, pass legislation to expand access to treatment, and establish prevention and support networks to address the heroin epidemic impacting the region.
This document provides a summary of a presentation on the risks of medical marijuana and marijuana legalization. It begins with disclosures from the presenters and outlines six learning objectives. It then discusses concerns that marijuana is addictive, especially for those who start using it early, and impacts adolescent brain development. The document notes the lack of evidence that marijuana is effective for the conditions it is claimed to treat. It also discusses the risks of increased diversion of marijuana to youth and greater social acceptance of marijuana use negatively impacting public health. The document concludes with messages on how to discuss these issues with the public.
This document provides information about an advocacy track presentation on advocating for change related to addiction issues. The presentation features Gary Mendell, founder and CEO of Shatterproof, and Kim Manlove from the Indiana Addictions Issues Coalition. They will discuss strategies for influencing legislation and how people in recovery can become advocates. The learning objectives focus on advocating for state laws on PDMP usage, explaining strategies to influence legislation, describing how people in recovery can advocate, and providing counsel as part of a treatment team. The presentation then provides details on Shatterproof's story, the overdose epidemic, solutions for different populations, and legislative accomplishments in various states related to expanding access to naloxone and mandating PDMP usage.
View only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdevaOPUNITE
This document summarizes a presentation on preventing hepatitis C and HIV outbreaks. It includes learning objectives about informing attendees of risks of infectious disease outbreaks related to injection drug use and describing collaborations between injury and infectious disease programs. The presentation features four speakers from Indiana and North Carolina public health departments and focuses on lessons learned from an HIV outbreak in Indiana linked to injection drug use.
This document summarizes a presentation on closing treatment gaps in the health care and criminal justice systems for opioid use disorders. It introduces the presenters and moderator and provides learning objectives focused on improving identification and treatment of opioid use disorders in health care settings and strategies for improving outcomes for frequently incarcerated individuals. Disclosures are provided for the presenters stating that they have no relevant financial relationships.
Rx16 prev wed_330_workplace issues and strategiesOPUNITE
This document discusses workplace issues related to prescription drug abuse and strategies for prevention. It begins with introductions of the presenters and moderators. The learning objectives are then outlined as understanding challenges of prescription drug abuse in the workplace, identifying prevention strategies, and describing programs available through SAMHSA. The document then covers topics such as the scope of prescription drug misuse among workers, risks to the workplace, prevention strategies employers can consider, and available resources from SAMHSA.
This document summarizes a presentation on managing morphine equivalent dose (MED) and identifying high-risk opioid use through "red flagging." It discusses how calculating MED at the point of sale can help identify unsafe dosages and decrease opioid prescriptions. It also evaluates different methods to screen for overdose risk, finding that simple opioid use thresholds to flag patients may not accurately target those most likely to experience preventable overdoses. The presentation aims to explain MED management, describe payer solutions that reduced opioid use, and identify more precise ways to intervene with highest-risk patients.
This document summarizes a presentation on drugs to watch including tramadol, hydrocodone, and naloxone. It includes:
- Disclosures from presenters declaring no conflicts of interest.
- Learning objectives focused on analyzing the impact of schedule changes for tramadol and hydrocodone, educating on tramadol dangers, and evaluating pharmacist perspectives on naloxone.
- Information presented on the drugs including their classifications, potencies, risks of abuse and addiction, and impacts of rescheduling hydrocodone and tramadol in California. Data showed decreased hydrocodone prescriptions but increased tramadol and overall opioid prescriptions, as well as increased over
Rx16 federal tues_200_1_gladden_2halpin_3greenOPUNITE
This document provides information about the emerging fentanyl overdose epidemic in the United States from the national and state perspectives. It discusses the rise in fentanyl-related overdoses and seizures from 2013-2014 according to data from various sources. The learning objectives are to explain the epidemiology of the rise in fentanyl overdoses, identify lessons from an Ohio investigation, and describe one state's experience. Recommendations include improving detection of fentanyl through testing and surveillance, expanding naloxone access, and long-term efforts to reduce opioid overdoses through prescribing guidelines and treatment expansion.
This document summarizes a presentation on health plan involvement in safe prescribing. It includes:
1) Presentations from medical experts on prescription drug abuse trends from medical examiner data and a tribal health system's safe prescribing program.
2) A discussion of health plan policies to reduce "red flag" medication combinations like opioids plus benzodiazepines through prior authorization, formulary changes, and provider restrictions.
3) Examples of one health plan's implementation of policies like restricting methadone prescriptions to pain specialists and removing carisoprodol from its formulary.
This document summarizes a presentation on medication-assisted treatment for opioid addiction. It discusses the history of treatment approaches, including the development of methadone and buprenorphine maintenance therapies. Studies show that agonist therapies like methadone and buprenorphine are more effective at retaining patients in treatment and reducing illicit opioid use than non-medication approaches. While both methadone and buprenorphine are effective, buprenorphine has a safer side effect profile but its effectiveness may be limited by lower monitoring and adherence compared to methadone treatment. The document reviews several studies demonstrating the benefits of long-term agonist therapy over detoxification or short-term medication approaches for opioid
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanOPUNITE
This document outlines an advocacy track presentation on activating communities to address prescription drug abuse. It provides biographies of the presenters and moderators and discloses any conflicts of interest. The learning objectives are to identify best practices for implementing CADCA's seven strategies for community change to impact prescription drug issues. It then provides examples of how various coalitions across the country are utilizing each of the seven strategies, such as providing education, enhancing skills, supporting communities, and changing policies.
The panel discussed two youth prevention programs - the Give Me a Reason voluntary drug testing program for parents and the This Is (Not) about Drugs prevention program implemented in schools. The Give Me a Reason program provides free at-home drug testing kits for parents to help prevent drug use among youth. The This Is (Not) about Drugs program uses a film and lesson plan to educate students about the risks of prescription opioid and heroin use with the goal of preventing first-time drug use.
This document summarizes a presentation on advances in treating chronic pain and addiction. It includes:
- Presenters from PRIUM, American Airlines, and the Treatment Research Institute
- Learning objectives around chronic pain, psychosocial issues, Medicaid requirements for the ASAM Criteria, and implementing the criteria
- Disclosures from presenters about relevant relationships
- Overview of topics like the bidirectional relationship between physical and mental health, impacts of adverse childhood experiences, and the influence of stigma on substance use treatment
- American Airlines' workers compensation program which saw a 40% reduction in claims and lower pharmacy costs and disability after redesigning their approach to focus on early intervention and additional resources for employees with chronic
Dr. Tom Frieden, Director of the Centers for Disease Control and Prevention, keynote presentation at the National Rx Drug Abuse & Heroin Summit on March 30, 2016.
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebranOPUNITE
This document summarizes a presentation on a study examining how prescriber registration and use of a prescription drug monitoring program (PDMP) in Oregon impacted opioid prescribing patterns and patient outcomes. The study found that statewide opioid prescribing generally decreased over time, but prescribers who registered for the PDMP prescribed more after registering, especially those who used the PDMP most frequently. In contrast, prescribers who did not register prescribed less. Patients whose providers were all registered had lower overdose rates than those with some registered and some non-registered providers. The conclusions were that PDMPs may need refinements like mandatory use to optimize their impact on prescribing and outcomes.
This document summarizes findings from interviews conducted as part of a study evaluating a chronic pain management pilot program for Medicaid patients in Rhode Island. Key findings include:
1) Patients reported that complementary and alternative therapies like acupuncture, massage and chiropractic care helped them better understand the relationship between stress and pain and provided an opportunity to build trusting relationships with providers.
2) Providers noted that the program allowed patients to receive hands-on care and personal connections that they may not receive otherwise due to lack of trust in the medical system and limited therapeutic relationships.
3) The program addressed transportation barriers by having some providers conduct home visits, improving access to care for patients with mobility issues.
4)
This document provides guidelines for handling referrals of sexual assault victims at the Accident and Emergency department of GTB hospital in Delhi, India. It states that female victims will be referred to the Gynecology and Obstetrics department for further management, while male victims will be treated in the main casualty area. It outlines procedures for consent, confidentiality, evidence collection and preservation, and duties of medical practitioners for such cases. It provides steps for specific cases like rape, including informing police, examination procedures, sample collection and preservation, and issuing medical certificates.
Medical Legal Aspects and Concerns of the Mid-Level PratcionerBernard Racey
Brief look at the legal aspects and concerns facing mid-level practioners (Physician Assistants and Nurse Practioners) in the United States Heath Care Systems
Improving the Safety of Your HealthcareNoel Eldridge
This is a set of slides I put together for a briefing for the Metro Maryland Ostomy Association. It is on the topic of patients being involved with their healthcare and focuses on improving safety and quality to the extent practicable by a patient. I am a member of the Board of MMOA, and had an ileostomy for 13 years, up until just a few months ago when I had "j-pouch" surgery. I worked for the Dept of VA's National Center for Patient Safety from 2000 to 2010, and have been with the AHRQ Center for Quality Improvement and Patient Safety 3 years as of this posting.
This document provides an overview of evidence-based medicine (EBM). It defines EBM as integrating the best research evidence with clinical expertise and patient values. The history and obstacles of EBM are discussed. The document outlines how to practice EBM using the 5 A's framework: Ask, Acquire, Appraise, Apply, and Assess. A case example is provided to demonstrate how to formulate a focused clinical question using the PICO format.
This document discusses patient abuse, including abuse of children and seniors. It defines patient abuse as the mistreatment or neglect of vulnerable individuals under a healthcare organization's care. Common signs of abuse include bruises, burns, broken bones, behavioral changes, and neglect that results in injuries. All states have laws requiring the mandatory reporting of suspected child and elder abuse in good faith to protect victims and provide legal immunity for reporters. Failure to report abuse can result in legal and ethical issues for healthcare providers.
This document discusses engaging the medical community on the issue of opioid use and abuse. It begins with introductions from Brian Fingerson, President of Kentucky Professionals Recovery Network, and Dallas Gay, Co-chair of the Medical Association of Georgia Foundation's "Think About It" Campaign. The speakers then review learning objectives about describing changing attitudes around prescription drug abuse, defining clinicians' roles in positively impacting the opioid epidemic, and demonstrating programs that are engaging the clinical community on appropriate opioid use and abuse.
Denial in cancer patients by Raquel Rodriguez Quintana Jonathan McFarland
Raquel is a Psycho-oncologist working at Son Llatzer Hospital, in Palma de Mallorca. In this presentation she talks about Denial In Cancer Patients; an important and fascinating talk.
This document is a health journal that allows the user to track important health information including medical history, test results, family health history, health goals, and lifestyle factors that impact health. It contains sections to document checkups, exams, screening tests, vaccinations, reproductive health, emotional health, domestic violence concerns, and emergency contacts. The overall purpose is to have a single place for a person to keep their medical records and health information to share with healthcare providers.
CDC Webinar: Foodborne illness Outbreaks and Law with Attorney Bill MarlerBill Marler
This document summarizes a presentation by William Marler on foodborne disease outbreaks and litigation. Some key points include:
- Foodborne pathogens cause an estimated 48 million illnesses annually in the US, costing $77.7 billion. However, actual cases are likely higher than reported.
- Outbreaks can be difficult to identify and link to a source. For example, only 4-8 regulatory actions result from thousands of clusters identified for E. coli O157:H7 and Salmonella.
- Litigation can provide an incentive to improve food safety practices, as seen in past outbreaks linked to companies like Odwalla and Jack in the Box. Public health investigations aim to stop outbreaks and prevent
The document discusses how patients can help improve healthcare through the use of technology and participation. It notes that patients are an underutilized resource in healthcare information systems and that giving patients access to their health records and engaging them can lead to improved health outcomes. The document advocates that patients should help define what high quality care means.
This document discusses informed consent. It begins by stating that obtaining informed consent is an important process in medical care and research. It then discusses some key principles of informed consent, including that it is a process of shared decision making between the subject and investigator, and involves the autonomous authorization of a medical intervention by individual patients. The document emphasizes that informed consent is not just a signed document, but an ongoing process.
This document discusses various ways to prove foodborne illness cases in court. It begins by explaining that Marler Clark only represents a small fraction of victims who contact them. It then discusses incubation periods of common foodborne pathogens. Several examples are provided of ways to prove a case, including using health department investigations of outbreaks, prior health inspection records, identifying improper food handling procedures, medical records, and lab tests like PFGE matching. The impacts of foodborne illness outbreaks like those from Odwalla and Jack in the Box are discussed, as well as how litigation can incentivize food safety. The Peanut Corporation of America salmonella outbreak and subsequent federal indictment are also summarized.
Patient confidentiality is crucial in healthcare and protected by laws like HIPAA. HIPAA ensures patient privacy and rights are upheld by enforcing penalties for violations, which can range from $100 per incident up to $1.5 million depending on the type of violation. Only authorized individuals like physicians and staff providing care, police, or those with court orders can access protected health information. Consent from the patient is also required before any procedures or information sharing and must be documented in writing.
This document describes a crisis intervention team working in an immigration detention unit. It provides context about the difficult living conditions for detainees and outlines the team's approach. The team uses Gestalt therapy principles and a six-step model of crisis intervention. This involves actively listening, ensuring safety, providing support, examining alternatives, making plans, and obtaining commitment from clients. The team works to help clients regain control during their crisis and restore equilibrium through creative adjustment.
Rape victim examination . Dr. Sharda Jain Lifecare CentreLifecare Centre
This document discusses the need for uniform examination protocols for rape victims in India conducted by female doctors. It notes the increasing rates of sexual assault and argues that victims need to speak up and that society's views of victims must change. It outlines new legal definitions of rape and guidelines for medical examinations, including use of a standard evidence collection kit. Key aspects are that injuries are not necessary to prove rape, and examinations should be sensitive, compassionate, and focus on medical care and collecting forensic evidence.
This document discusses definitions of abnormal behavior and mental illness. It examines three proposed definitions: conformity to norms, subjective distress, and disability or dysfunction. For each definition, examples are provided and advantages and problems are discussed. Ultimately, no single definition can encompass all cases of abnormal behavior, and abnormal behavior does not necessarily indicate mental illness. Mental illness is also difficult to define precisely.
Top 10 Question from Ch 6 of Kotler's Marketing Management Bookzennia
The document contains a set of learning questions and answers about factors that influence consumer behavior such as cultural, social, personal, and behavioral influences. It also discusses concepts like reference groups, subculture influences, brand personality, motivation theories, consumer decision making processes, and how consumers use and dispose of products.
Health & wealth agenda of the provincial federation of ABCsArnulfo Laniba
This document outlines the agenda of the Provincial Federation of ABCs to combat poor health and wealth issues. It discusses the current dismal state of disease, death, poverty, and bankruptcy, and identifies the medical-pharmaceutical system as failing and as the number one cause of death in America. Alternative approaches focusing on preventive medicine using natural remedies are presented. The wellness industry and networking are proposed as the main strategies to tackle these problems.
Similar to Web only rx16 presummit pillmills-mon_200_investigating and prosecuting pill mills (20)
Kana Enomoto, Acting Administrator, Substance Abuse and Mental Health Services Administration, keynote presentation at the National Rx Drug Abuse & Heroin Summit March 29, 2016
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingOPUNITE
This document discusses the role of health departments in preventing neonatal abstinence syndrome (NAS). It notes that NAS rates have increased significantly in recent years, disproportionately affecting women. Health departments engage in surveillance to monitor NAS trends, partner with other organizations, support treatment and recovery programs, and provide education to prevent NAS, which is entirely preventable. The document outlines specific strategies health departments use across these areas to address the opioid epidemic and protect maternal and infant health.
The document discusses the opioid crisis in the United States, including rising rates of prescription opioid misuse and abuse, as well as heroin use and overdose deaths. It outlines how research can help address this crisis through developing less abusable analgesics, expanding access to treatment medications like naloxone and buprenorphine, and exploring new treatment approaches such as immunotherapies and precision medicine targeting genetic factors. The National Institute on Drug Abuse is supporting these research efforts and working to disseminate findings to improve prevention and intervention programs.
This document summarizes the opioid crisis in the United States from 2000 to 2014. It shows that the number of opioid-related overdose deaths more than tripled during this period, increasing from about 8,000 to over 28,000. Additionally, 7.9 million Americans aged 12 or older met the criteria for an illicit drug use disorder in 2013-2014 but only 20% received treatment. The document outlines actions by the Obama administration to address the crisis and increase funding for treatment. It emphasizes that stories can help reduce stigma and that recovery is possible through working together.
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyOPUNITE
This presentation covered multi-media prevention strategies for issues like prescription drug overdoses. It discussed the CDC's digital Rx drug prevention campaign, best practices for digital messaging, and programs using expectancy challenge theory and media literacy education in schools. Presenters included representatives from the CDC, Media Literacy for Prevention, and the Hanley Center Foundation who discussed their work developing and implementing digital communications and single-session prevention programs.
This document summarizes a presentation on linking and mapping prescription drug monitoring program (PDMP) data. It discusses the benefits of linking PDMP data to clinical data, including improving patient safety, evaluating prescribing decisions, and assessing the impact of PDMP interventions. It describes challenges with linking data, such as obtaining consent and negotiating data use agreements. It also discusses Washington State's MAPPING OPIOID AND OTHER DRUG ISSUES (MOODI) tool, which integrates PDMP data with other databases to map and target treatment and overdose prevention efforts at the community level.
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessOPUNITE
This document discusses a presentation on pharmacy burglary, robbery, and diversion of prescription drugs. The presentation covers trends in prescription drug diversion, particularly those involving robbery and burglary of pharmacies. It identifies preventative measures to enhance pharmacy security and safety. Strategies to reduce pharmacy crimes are outlined. The offender perspective is examined based on interviews with convicted offenders. Routine activities theory is discussed as relating to suitable targets, capable guardians, and motivated offenders. Partnerships between regulatory agencies and law enforcement are emphasized as key to prevention efforts.
Linking and mapping PDMP data can provide several benefits but also faces challenges. Linking PDMP and clinical data allows for evaluating the impact of PDMP interventions on outcomes and prescribing decisions. However, obtaining permissions and data is difficult due to legal and resource barriers. Mapping PDMP data using GIS tools in Washington identified areas for targeting overdose prevention efforts by visualizing patterns in prescribing risks, treatment availability, and overdoses. Stakeholders used these maps to guide education and funding decisions. Sustaining these tools requires ongoing funding and expanding included data sources.
This document discusses neonatal abstinence syndrome (NAS) and universal maternal drug testing. It provides background information on NAS including trends showing large increases in incidence and costs associated with NAS. It outlines objectives related to describing NAS trends, identifying legislative activities impacting NAS, describing family planning for women in substance abuse treatment, and explaining a hospital program using universal drug testing. The document then covers topics including NAS symptoms, incidence and geographic trends, costs of NAS, opioid use in women of childbearing age, unintended pregnancy rates, contraceptive use among opioid users, and maternal drug exposure sources.
This document discusses recovery ready ecosystems and recovery community organizations. It introduces presenters from Young People in Recovery and Hope House Treatment Track who will discuss interventions, prevention, and recovery programs. Examples of Young People in Recovery chapters, programs, and services are provided, including employment workshops, education workshops, housing workshops, and recovery support services. The document also discusses recovery community organizations and initiatives in Texas and Georgia, such as the Association of Persons Affected by Addiction in Dallas and the Georgia Council on Substance Abuse.
This document summarizes a presentation on youth performance-enhancing drugs and ADHD medication. It discusses trends in misuse of these substances among young people. The presentation is given by representatives from various organizations focused on prevention, health promotion, and substance abuse issues among youth and college students. The presentation covers types of performance-enhancing drugs and their potential side effects. It also discusses trends in attitudes towards these substances and risks of misuse. Strategies are presented for helping adolescents pursue their goals without these drugs. The document concludes by outlining plans for addressing misuse of ADHD medication among college students through education and collaboration between various stakeholder groups.
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachioOPUNITE
Community pharmacists are well positioned to help address the growing problem of opioid and benzodiazepine addiction but face challenges. Early identification of at-risk patients, supportive benefit structures, and intervention training could empower pharmacists. While many recognize their responsibility, behavioral engagement in prevention is often lacking due to practice barriers, lack of patient information, and fear of responses. Standardizing communication expectations and screening tools could help pharmacists better fulfill their role on the treatment team.
1. Two states, South Carolina and Wisconsin, improved integration of PDMP data into electronic health systems by establishing connections between their PDMPs and various health IT platforms like EMR systems and pharmacy dispensing software.
2. States face challenges with PDMP integration like legal definitions of access, costs of integration projects, and establishing necessary agreements and user authorizations.
3. Florida operates drug surveillance systems through a medical examiners commission and PDMP. Analysis found declines in prescription opioid overdoses after implementation of legislative and regulatory interventions including a PDMP in 2011. However, heroin overdose deaths increased as some shifted to heroin.
Web only rx16 len wed_200_1_augustine_2napier_3darr - copyOPUNITE
This document summarizes a presentation about the Handle with Care program, which aims to help children who have been exposed to trauma. The presentation discusses how drug abuse and violence impact children, showing statistics on drug seizures and crimes in certain areas. It then describes the Handle with Care program, where law enforcement notifies schools of children who were exposed to a traumatic event so the school can provide trauma-informed support. School interventions discussed include therapy dogs, academic accommodations, and on-site therapy. The presenters emphasize that Handle with Care aims to help children succeed in school by providing trauma-sensitive support.
Rx16 federal wed_1230_1_kelly_2bohn-killorinOPUNITE
1) The National HIDTA Program provides assistance to law enforcement agencies in critical drug trafficking regions through 28 regional HIDTA programs. It facilitates cooperation among federal, state, local, and tribal law enforcement.
2) Each HIDTA program has an executive board that identifies threats, develops strategies, and requests funding for initiatives. It brings together over 7,400 federal agents, 15,700 state and local officers, and 500 agencies across the country.
3) In response to the opioid epidemic, HIDTA employs law enforcement targeting of heroin and fentanyl trafficking, public health prevention efforts, and training on investigating heroin organizations. It has committed additional funds to enhance intelligence sharing and public health partnerships.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Our backs are like superheroes, holding us up and helping us move around. But sometimes, even superheroes can get hurt. That’s where slip discs come in.
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Web only rx16 presummit pillmills-mon_200_investigating and prosecuting pill mills
1. Investigating and
Prosecuting Pill Mills
Presenters:
•Jennifer Doll, Special Agent, California Department of Justice
•John Niedermann, JD, Deputy District Attorney, Los Angeles
County District Attorney’s Office
Pre-Summit Workshop
Moderator: Karen L. Kelly, District Director, Congressman Harold
“Hal” Rogers (KY-5th District), and Member, Rx and Heroin Summit
National Advisory Board
2. Disclosures
Jennifer Doll; John Niedermann, JD; and Karen L.
Kelly have disclosed no relevant, real, or
apparent personal or professional financial
relationships with proprietary entities that
produce healthcare goods and services.
3. Disclosures
• All planners/managers hereby state that they or their
spouse/life partner do not have any financial
relationships or relationships to products or devices
with any commercial interest related to the content of
this activity of any amount during the past 12 months.
• The following planners/managers have the following
to disclose:
– John J. Dreyzehner, MD, MPH, FACOEM – Ownership
interest: Starfish Health (spouse)
– Robert DuPont – Employment: Bensinger, DuPont &
Associates-Prescription Drug Research Center
4. Learning Objectives
1. Identify challenges and strategies related to
investigating a provider Rx drug case.
2. Distinguish the possible charges that could
be filed.
3. Explain how to prepare for and prosecute a
criminal trial against a medical professional.
6. --How investigations are initiated
-Constructing an investigation plan
-Identifying Drugs
-Conducting the investigation
-Collecting evidence
-Putting it all together
-Prosecution and legal issues
Course Overview:Course Overview:
7. PEOPLE V. TSENGPEOPLE V. TSENG (LESS THAN 3 YEARS)(LESS THAN 3 YEARS)
PC 187
PC 187
PC 187
PC 187
PC 187
PC 187
10. SPECIAL AGENT ROBERT HARKINS
BEGAN INVESTIGATION IN SEPTEMBER OFBEGAN INVESTIGATION IN SEPTEMBER OF
2008:2008:
TIPPED OFF BY LOCAL PHARMACISTSTIPPED OFF BY LOCAL PHARMACISTS
CONDUCTED SURVEILLANCE ON THE CLINICCONDUCTED SURVEILLANCE ON THE CLINIC
REVEALED LINES OF YOUNG PEOPLEREVEALED LINES OF YOUNG PEOPLE
SET UP A SERIES OF UNDERCOVERSET UP A SERIES OF UNDERCOVER
OPERATIONSOPERATIONS
11. INITIATION OFINITIATION OF
INVESTIGATIONINVESTIGATION
DEATH OF A PATIENTDEATH OF A PATIENT
--Report from a coroner (802.5)Report from a coroner (802.5)
-Family member reports death-Family member reports death
-Law enforcement-Law enforcement
12. RYAN LATHAMRYAN LATHAM
KELLY RALPHKELLY RALPH::
Had back pain with unknown source but appearedHad back pain with unknown source but appeared
to be a sports injury.to be a sports injury.
Thought 5 hydrocodone per day was safe.Thought 5 hydrocodone per day was safe.
DECEASED
DECEASED
14. CRIMINAL VERSUS ADMINSTRATIVE ACTIONSCRIMINAL VERSUS ADMINSTRATIVE ACTIONS
Over Prescribing
Fraudulent Prescribing
Money Laundering / Structuring
Tax Fraud
Insurance Fraud
Prescribing Without a Legitimate Medical Purpose
Prescribing to Addicts
Homicide
Sales/Distribution of Controlled Substances
Unlicensed Practice of Medicine
21. INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES
A pharmacist should act as a second screener and is obligated
to verify prescriptions in which the legitimacy is questioned.
A pharmacist has obligations to go over proper usage of
medications in the form of “patient consultations.”
22. PHARMACISTSPHARMACISTS
ALFONSO VERCUEIL ANGELA LI LYDIA BRAY KIMBERLY QUACH
• YOUNG WHITE MALESYOUNG WHITE MALES
• PAYING LARGE AMOUNTS OF CASHPAYING LARGE AMOUNTS OF CASH
• ASKING FOR BRAND NAMESASKING FOR BRAND NAMES
• APPEARING HEALTHYAPPEARING HEALTHY
• REQUESTING UNUSUAL COMBINATIONS OF DRUGSREQUESTING UNUSUAL COMBINATIONS OF DRUGS
• SOME APPEARED UNDER THE INFLUENCESOME APPEARED UNDER THE INFLUENCE
• SOME APPEARED ANXIOUS OR AGITATEDSOME APPEARED ANXIOUS OR AGITATED
ANGELA LIANGELA LI: THE NUMBER OF PRESCRIPTIONS DID NOT DROP: THE NUMBER OF PRESCRIPTIONS DID NOT DROP
EVEN AS SHE WAS REFUSING THEMEVEN AS SHE WAS REFUSING THEM
LYDIA BRAYLYDIA BRAY: IN 38 YEARS SHE HAS NEVER SEEN QUANTITIES: IN 38 YEARS SHE HAS NEVER SEEN QUANTITIES
AND STRENGTH LIKE THIS AND HASN’T SINCEAND STRENGTH LIKE THIS AND HASN’T SINCE
25. INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES
Toxicology results are often provided with an autopsy report.
Typically, a 1 page summary report is provided with the end results
of the tests.
Be cautious of who signs the toxicology report, as MULTIPLE
toxicologists most likely ran tests and may not have signed the
report.
TOXICOLOGY
26. INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES
Find out the lab’s retention policies and request that the
samples for your case be held longer if necessary.
Get information of chain of custody. Whose hands touched
the vial?? TOXICOLOGY
31. INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES
Witnesses: The Interview
How did the patient hear about the subject?
Did the patient have a legitimate medical condition?
How far did the patient travel to the clinic?
How did they pay? Cash? Insurance?
How long did they wait to see the subject versus length of exam?
Did the subject recommend a specific pharmacy?
Did the patient reveal a history of addiction to the subject? When?
Show the patient a 6-pack and ask that they identify the subject
Did they consume the pills? Sell?
32. INVESTIGATIVE RESOURCESINVESTIGATIVE RESOURCES
Be sensitive to their needs / fears /
hesitations
Don’t judge their addiction or behaviors to
obtain medication
Talk to your prosecutor about witness
concerns and discuss immunity (case by
case basis)
Witnesses
33.
34. “Holy TrinityHoly Trinity” – combination of three
drugs (Soma, Xanax, Vicodin) which
create a euphoria like heroin
IDENTIFYING DRUGSIDENTIFYING DRUGS
35. Addiction CertificateAddiction Certificate
Methadone prescribed for addiction requires a special
certificate issued through the DEA
(Methadone prescribed for pain does not require this
certificate, however the use of the medication must be
documented in the chart)
IDENTIFYING DRUGSIDENTIFYING DRUGS
36. IDENTIFYING DRUGSIDENTIFYING DRUGS
Identify Drugs in your Investigation Report
Include a brief summary identifying
drugs in your case
Include brand name, generic name and
schedule
Note for what condition drug is used
Cite current schedule at the time the
drug was dispensed or administered
37.
38. THE UNDERCOVER OPERATIONS
SPECIAL AGENT STEPHANIE MORELANDSPECIAL AGENT STEPHANIE MORELAND APRIL 25, 2008APRIL 25, 2008
• TOLD DEFENDANT SHE NEEDED SOMETHING FOR CRAMPS
AND A HEADACHE
• TOLD THE DEFENDANT SHE WAS COMING FROM
OCEANSIDE
• NO PHYSICAL EXAM WAS GIVEN
• DEFENDANT SAID SHE WOULD PRESCRIBE VICODIN TO
TAKE THE EDGES OFF
UNCHARGEDUNCHARGED
39. Pain vs No pain
Recording Devices (should you have them? Where
should you put them?)
How many buys are necessary?
Establishing a rapport the doctor
Testifying after your U/C
Entrapment / Red flags
Undercover Investigations: IssuesUndercover Investigations: Issues
CONDUCTING THE INVESTIGATIONCONDUCTING THE INVESTIGATION
41. CONDUCTING THE INVESTIGATIONCONDUCTING THE INVESTIGATION
SEARCH WARRANTSSEARCH WARRANTS
What are you trying to obtain?
What probable cause is needed to obtain those
items?
Do you have probable cause?
Can you ever have too much information in a SW?
Tools to assist with SW writing
PREPARING SEARCH WARRANTSPREPARING SEARCH WARRANTS
43. CONDUCTING THE INVESTIGATIONCONDUCTING THE INVESTIGATION
SEARCH WARRANTSSEARCH WARRANTS
Getting your warrant signed
- Finding a judge
- Educating your judge
- Know your case (the judge will probably ask questions)
46. COLLECTING EVIDENCECOLLECTING EVIDENCE
EXECUTING A WARRANT
Securing the evidence:
If computer equipment is expected to be
taken, consider staff / subject destroying
evidence upon entry.
Do you have a technical team that can safely
remove digital data without compromising
the data?
47. COMPUTER RECORDSCOMPUTER RECORDS
COLLECTING EVIDENCECOLLECTING EVIDENCE
Specific language in SW to search computer files
Agency assist in collection of files
Agency assist in analyzing data- DOJ, FBI, locals,
etc.
Consider turn around time for data to be recovered
Search warrant return – language for additional
time for digital data
Consider the cloud
50. WHO WAS THEREWHO WAS THERE
PHYSICIANPHYSICIAN WAS THE DOCTOR WITH AWAS THE DOCTOR WITH A
PATIENTPATIENT
WAS THE DOCTORWAS THE DOCTOR
COOPERATIVECOOPERATIVE
DID THE DOCTOR SUBMIT TODID THE DOCTOR SUBMIT TO
BE INTERVIEWEDBE INTERVIEWED
DOES THE DOCTOR HAVE ADOES THE DOCTOR HAVE A
PRIOR RECORDPRIOR RECORD
WHAT WAS THEIR CHIEF AREAWHAT WAS THEIR CHIEF AREA
OF PRACTICEOF PRACTICE
WHAT BOARDWHAT BOARD
CERTIFICATIONS DO THEYCERTIFICATIONS DO THEY
HAVEHAVE
51. WHO WAS THEREWHO WAS THERE
PHYSICIAN’S ASSISTANTPHYSICIAN’S ASSISTANT
WAS HE SEEING PATIENTSWAS HE SEEING PATIENTS
WHAT DUTIES WEREWHAT DUTIES WERE
DELEGATED TO HIMDELEGATED TO HIM
IS THERE A DELEGATION OFIS THERE A DELEGATION OF
SERVICES AGREEMENTSERVICES AGREEMENT
WHAT IS HIS SKILL SETWHAT IS HIS SKILL SET
WHAT HOURS DOES HE WORK INWHAT HOURS DOES HE WORK IN
RELATION TO THE DOCTORRELATION TO THE DOCTOR
52. WHO WAS THEREWHO WAS THERE
MEDICAL ASSISTANTMEDICAL ASSISTANT
RECEPTIONISTRECEPTIONIST
WHAT ARE THEIR DUTIESWHAT ARE THEIR DUTIES
DO THEY HAVE MEDICALDO THEY HAVE MEDICAL
TRAININGTRAINING
HOW DO THEY INTERACT WITHHOW DO THEY INTERACT WITH
PATIENTSPATIENTS
WHO DOES BOOKKEEPINGWHO DOES BOOKKEEPING
HOW ARE RECORDS KEPTHOW ARE RECORDS KEPT
HOW DOES THE FRONT OF THEHOW DOES THE FRONT OF THE
OFFICE RUNOFFICE RUN
WHAT TYPES OF PATIENTS AREWHAT TYPES OF PATIENTS ARE
SEENSEEN
53. WHO WAS THEREWHO WAS THERE
RUNNERSRUNNERS
CAPPERSCAPPERS
WHAT ARE THEIR DUTIESWHAT ARE THEIR DUTIES
HOW WERE THEY TRAINEDHOW WERE THEY TRAINED
HOW ARE THEY PAIDHOW ARE THEY PAID
WHAT IS THEIR RELATIONSHIP TOWHAT IS THEIR RELATIONSHIP TO
THE DOCTORTHE DOCTOR
61. SPECIFIC MEDICALSPECIFIC MEDICAL
RECORDS LISTED BYRECORDS LISTED BY
PATIENTPATIENT
Include a description of
what a medical record is.
(i.e. physical / electronic
charts, x-rays, phone
messages, insurance
billing, labs,
prescriptions, etc)
COLLECTING EVIDENCECOLLECTING EVIDENCE
66. WHERE EVIDENCE WAS RECOVEREDWHERE EVIDENCE WAS RECOVERED
IN A DRAWER:IN A DRAWER:
WAS IT CLOSED (KNOWLEDGE)WAS IT CLOSED (KNOWLEDGE)
WAS IT LOCKED (ACCESS)WAS IT LOCKED (ACCESS)
IN WHAT AREA OF THE CLINIC (POSSESSION/CONTROL)IN WHAT AREA OF THE CLINIC (POSSESSION/CONTROL)
WHO HAD KEYS (SHARED RESPONSIBILITY/DELEGATION)WHO HAD KEYS (SHARED RESPONSIBILITY/DELEGATION)
67. WHERE EVIDENCE WAS RECOVEREDWHERE EVIDENCE WAS RECOVERED
ON A SHELF:ON A SHELF:
HOW WERE THE RECORDS ARRANGED (STANDARD OFHOW WERE THE RECORDS ARRANGED (STANDARD OF
CARE)CARE)
WHO WAS RESPONSIBLE FOR MAKING NOTATIONSWHO WAS RESPONSIBLE FOR MAKING NOTATIONS
(KNOWLEDGE)(KNOWLEDGE)
WHO HAD ACCESS TO THE RECORDS (DELEGATION)WHO HAD ACCESS TO THE RECORDS (DELEGATION)
68. WHERE EVIDENCE WAS RECOVEREDWHERE EVIDENCE WAS RECOVERED
IN A BATHROOM:IN A BATHROOM:
WHO HAD ACCESS (STANDARD OF CARE)WHO HAD ACCESS (STANDARD OF CARE)
WERE CONTROLLED SUBSTANCES MIXED WITH NON-WERE CONTROLLED SUBSTANCES MIXED WITH NON-
CONTROLLED SUBSTANCES (NEGLIGENCE)CONTROLLED SUBSTANCES (NEGLIGENCE)
69. WHERE EVIDENCE WAS RECOVEREDWHERE EVIDENCE WAS RECOVERED
IN A PILL ROOM:IN A PILL ROOM:
WERE THERE LOOSE PILLS (NEGLIGENCE)WERE THERE LOOSE PILLS (NEGLIGENCE)
WERE THERE NON-MEDICAL ITEMS LOCATEDWERE THERE NON-MEDICAL ITEMS LOCATED
(STANDARD OF CARE)(STANDARD OF CARE)
WHO HAD ACCESS TO THE ROOM (CONTROL)WHO HAD ACCESS TO THE ROOM (CONTROL)
70. WHERE EVIDENCE WAS RECOVEREDWHERE EVIDENCE WAS RECOVERED
IN A CAR:IN A CAR:
WERE ITEMS LOCKED AND SECURED (STANDARD OFWERE ITEMS LOCKED AND SECURED (STANDARD OF
CARE)CARE)
WERE ITEMS LABELED OR SCRIPTS FILLED OUTWERE ITEMS LABELED OR SCRIPTS FILLED OUT
(MOTIVE)(MOTIVE)
75. PHARMACIST
STEVE
MAZLIN
INTERVIEWS WITH PHARMICISTS:INTERVIEWS WITH PHARMICISTS:
WARNINGSWARNINGS
Chloral Hydrate is a veryChloral Hydrate is a very
powerful respiratorypowerful respiratory
suppressant. You don’t wantsuppressant. You don’t want
to end up on the cover of theto end up on the cover of the
“National Inquirer.”“National Inquirer.”
I had to correct Dr. Eroshevich onI had to correct Dr. Eroshevich on
the dosing on her prescription.the dosing on her prescription.
COLLECTING EVIDENCECOLLECTING EVIDENCE
77. ANNA NICOLE SMITH’S MEDICAL HISTORYANNA NICOLE SMITH’S MEDICAL HISTORY HOWARD K. STERN’S MEDICAL HISTORYHOWARD K. STERN’S MEDICAL HISTORY
INTAKE PATIENT PROFILESINTAKE PATIENT PROFILES
COLLECTING EVIDENCECOLLECTING EVIDENCE
85. Coroner’s Reports
Witness / family statements made to coroner investigators
Admissions of doctor to coroner staff / investigators
Coroner investigator notes (not included in autopsy report)
Photos:
COLLECTING EVIDENCECOLLECTING EVIDENCE
89. COLLECTING EVIDENCECOLLECTING EVIDENCE
EXPERT OPINIONS
Once evidence is obtained, determine if an
expert opinion is necessary.
Make sure the expert has the entire picture of
the case, not just a snap shot (for example, just
having an expert review a PDMP report)
90. COLLECTING EVIDENCECOLLECTING EVIDENCE
EXPERT OPINIONS
Expert opinions are critical to most over-prescribing cases.
Consider the strength of your case depending on your
expert’s findings: no departure, simple departure, extremeno departure, simple departure, extreme
departure and lack of knowledgedeparture and lack of knowledge
91. DR. WALTER STRAUSERDR. WALTER STRAUSER
THE STANDARD OF CARETHE STANDARD OF CARE
“THE LEVEL OF SKILL, KNOWLEDGE AND
CARE IN DIAGNOSING AND TREATING
THAT A REASONABLY PRUDENT
PHYSICIAN WOULD EXERCISE IN SIMILAR
CIRCUMSTANCES.”
THE SAME STANDARD OF CARE APPLIES TO ALL
PHYSICIANS
AN EXTREME DEPARTURE FROM THE STANDARD OF
CARE:
GROSS NEGLIGENCE AND LACK OF SCANT CARE
92. No inquiry into who the other doctors were
and why so much medication at his age
MEDICAL OPINIONSMEDICAL OPINIONS
EXTREME DEPARTUREEXTREME DEPARTURE
COLLECTING EVIDENCECOLLECTING EVIDENCE
97. FELONY MURDERFELONY MURDER
+TheThe unlawful killingunlawful killing of a human being,of a human being,
+WhetherWhether intentionalintentional,, unintentionalunintentional, or, or
accidentalaccidental,,
+WhichWhich occurs duringoccurs during the commissionthe commission
or attempted commission of a felony,or attempted commission of a felony,
+When the perpetrator had theWhen the perpetrator had the specificspecific
intentintent toto commit that specified felonycommit that specified felony
= MURDER
98. FELONY MURDERFELONY MURDER
+TheThe unlawful killingunlawful killing of a human being,of a human being,
+WhetherWhether intentionalintentional,, unintentionalunintentional, or, or
accidentalaccidental,,
+WhichWhich occurs duringoccurs during the commissionthe commission
or attempted commission of felony,or attempted commission of felony,
+When the perpetrator had theWhen the perpetrator had the specificspecific
intentintent toto commit that specified felonycommit that specified felony
= MURDER
CALIFORNIACALIFORNIA
OVER-PRESCRIBING STATUTESOVER-PRESCRIBING STATUTES
101. SECOND DEGREE MURDER
DANGEROUS TO LIFE
1. The killing resulted from an intentional act,
2. The natural consequences of the act are
dangerous to human life, and
3. The act was deliberately performed with
knowledge of the danger to, and with conscious
disregard for, human life.
• When the killing is the direct result of such an act, it isWhen the killing is the direct result of such an act, it is
not necessary to prove that the defendant intended thatnot necessary to prove that the defendant intended that
the act would result in the death of a human being.the act would result in the death of a human being.
105. MICHAEL COOKMICHAEL COOK
It never took long in the exam room and no
physical exam was done. Started adding
prescriptions to what I wanted. Overdosed 3
times in 2 days, the last time
in the restroom at AAA.
106. MICHAEL COOKMICHAEL COOK
Went to clinic on April 25, 2008.
Patient’s screen was positive
for opiates. Doctor said he’d taken
6 Opana yesterday.
MATTHEW BRIONESMATTHEW BRIONES
107. NAYTHAN KENNEYNAYTHAN KENNEY
ERIN WHITNEY:
•DOCTOR’S RECEPTION AREA LOOKED
LIKE A PAROLE OFFICE
• PEOPLE IN THERE HAD LOTS OF
TATTOOS
• DRUG DEALING AND PEOPLE
EXCHANGING NUMBERS
• 2 TO 3 PEOPLE IN EACH EXAM ROOM
•SHE RECEIVED PRESCRIPTIONS FROM
THE DEFENDANT WITH NO EXAM, NO X-
RAYS
109. NAYTHAN KENNEYNAYTHAN KENNEY
STRAUSERSTRAUSER
No medical record except date of
visit, blood pressure and pulse or no
examination of the patient while
giving controlled substances is an
Extreme Departure from the standard
of care. It falls outside the scope of
practice.
112. CREATING A CAPTIVE AUDIENCECREATING A CAPTIVE AUDIENCE
MICHAEL COOK: WITHDRAWAL IS HELL. THE BODY GETS
WEAKER AND THE TOLERANCE GROWS. IT’S AN EQUATION FOR
DISASTER.
JUSTIN SMITH: WOULD WAIT 2-3 HOURS EACH TIME BECAUSE HE
NEEDED TO GET HIS MEDICATION. WHEN YOU ARE ADDICTED,
YOU DON’T REALLY CARE WHAT YOU TAKE OR WHAT YOU DO. IF
IT MAKES YOU NORMAL OR HIGH, THEN IT WORKS. AND THERE IS
A RISK OF DYING ALMOST EVERY DAY.
LANA RAU: FELT LIKE SHE WAS GOING THROUGH WITHDRAWALS
EVERY MORNING AND NEEDED THE MEDICATION JUST TO FEEL
NORMAL.
ALEXANDER HUY: HE WOULD WAIT UP TO 6 HOURS JUST TO GET
HIS PRESCRIPTION.
113. DR. EZEKIEL FINKDR. EZEKIEL FINK
IMPACT OF NOTIFICATION OF AIMPACT OF NOTIFICATION OF A
PATIENT DEATH ON THEPATIENT DEATH ON THE
PRACTICE OF MEDICINEPRACTICE OF MEDICINE
““I THINK THAT A PATIENT DYING INI THINK THAT A PATIENT DYING IN
ONE’S CARE WOULD HAVE AONE’S CARE WOULD HAVE A
PROFOUND IMPACT AND WOULD MAKEPROFOUND IMPACT AND WOULD MAKE
ME GO BACK AND TRY TO FIGURE OUTME GO BACK AND TRY TO FIGURE OUT
IF THERE WAS SOMETHING THATIF THERE WAS SOMETHING THAT
COULD HAVE BEEN DONE DIFFERENTCOULD HAVE BEEN DONE DIFFERENT
TO PREVENT THAT DEATH.”TO PREVENT THAT DEATH.”
““DIDN’T CREATE AN ISSUE IN THE OFFICE. WASDIDN’T CREATE AN ISSUE IN THE OFFICE. WAS
AN ORDINARY CALL, MOSTLY FYI.”AN ORDINARY CALL, MOSTLY FYI.”
Dr. Gene Tu
114. GLORIA RODRIGUEZGLORIA RODRIGUEZ
CASH INCREASEDCASH INCREASED
FROM $500-$600 PERFROM $500-$600 PER
DAYDAY
TO $2,000 SOMETIMESTO $2,000 SOMETIMES
$3,000 PER DAY$3,000 PER DAY
““They’re druggies, theyThey’re druggies, they
can wait.”can wait.”
PER ADVANCED CAREPER ADVANCED CARE
AAA TAX RETURNSAAA TAX RETURNS
2007-20102007-2010
+ $5,000,000+ $5,000,000
117. CASES OF INTERESTCASES OF INTEREST
PEOPLE V. ESTIANDANPEOPLE V. ESTIANDAN PEOPLE V. KAPOOR, STERN & EROSEVICHPEOPLE V. KAPOOR, STERN & EROSEVICH
PEOPLE V. MURRAYPEOPLE V. MURRAY PEOPLE V. TSENGPEOPLE V. TSENG
121. PEOPLE V. CARLOS ESTIANDANPEOPLE V. CARLOS ESTIANDAN
13 FELONY COUNTS OF PRESCRIBING
WITHOUT A LEGITIMATE MEDICAL
PURPOSE
1 FELONY COUNT OF PRESCRIBING TO AN ADDICT
CONVICTEDCONVICTED
BY JURY OFBY JURY OF
ALL 14ALL 14
COUNTSCOUNTS
122. ISSUESISSUES
FORMER ADDICT AND “PATIENT” AS A WITNESS
ENTRAPMENT DEFENSE
LESLIE GREENBERGLESLIE GREENBERG
DEPUTY LEO NOYOLADEPUTY LEO NOYOLA
123. CONSPIRACYCONSPIRACY
A conspiracy is an agreement entered into between two or more
persons with the specific intent to agree to commit a crime, followed
by an overt act committed in this state by one or more of the parties
for the purpose of accomplishing the object of the agreement.
Conspiracy is a crime.
WHAT IS A CONSPIRACY?WHAT IS A CONSPIRACY?
124. PEOPLE V. KAPOOR, EROSEVICH AND STERNPEOPLE V. KAPOOR, EROSEVICH AND STERN
127. 3 COUNTS OF SECOND DEGREE MURDER3 COUNTS OF SECOND DEGREE MURDER
20 FELONY PRESCRIBING COUNTS20 FELONY PRESCRIBING COUNTS
128. DR. EZEKIEL FINKDR. EZEKIEL FINK
ON KNOWLEDGE OF ABUSE
“WHEN A PATIENT COMES IN AND TELLS
YOU THAT THEY’RE AN ACTIVE HEROIN
ADDICT, YOU CANNOT TURN AROUND,
HAND THEM A PRESCRIPTION, AND SAY, ‘I
JUST HAD NO CONTROL OF THAT
PRESCRIPTION.’”
“THE PATIENT TOLD YOU THEY DIDN’T HAVE
CONTROL. YOU HAD THE OPPORTUNITY TO
ACTUALLY MAKE A CHANGE AND BRING THEM BACK
FROM THAT CLIFF, BUT YOU PUSHED THEM.”
129. SEPTEMBERSEPTEMBER
20082008
KENNEYKENNEY NGUYENNGUYEN
MARCHMARCH
20092009
5 ½ MONTHS5 ½ MONTHS 4 WEEKS4 WEEKS
OGLEOGLE
APRILAPRIL
20092009
KATSNELSONKATSNELSON
APRILAPRIL
20092009
8 DAYS8 DAYS
ROVEROROVERO
DECEMBERDECEMBER
20092009
8 MONTHS8 MONTHS
PATTERNPATTERN
APPRECIATION OF THE RISK/CONSCIOUS DISREGARDAPPRECIATION OF THE RISK/CONSCIOUS DISREGARD
133. OUT ON BAILOUT ON BAIL
DR. THOMAS LINDR. THOMAS LIN
$450,000$450,000
$1,000,000$1,000,000 PHARMACY AUDITPHARMACY AUDIT
HEALTH & SAFETYHEALTH & SAFETY
CODECODE
1115511155
134. OUT ON BAILOUT ON BAIL
$120,000$120,000
DR. GERARD GORYLDR. GERARD GORYL
135. DR. GERARD GORYLDR. GERARD GORYL
$1,000,000$1,000,000
OUT ON BAILOUT ON BAIL
136. OUT ON BAILOUT ON BAIL
DR. GERARD GORYLDR. GERARD GORYL
$2,000,000$2,000,000
137. CONCLUDING CONSIDERATIONS FOR FILINGCONCLUDING CONSIDERATIONS FOR FILING
SPECIFIC CRIMINAL INTENT
STRENGTH OF EVIDENCE
NUMBER OF VICTIMS
RESOURCES NEEDED TO PROSECUTE
PRIOR CRIMINAL BEHAVIOR
POTENTIAL DEFENSES
138. Administrative discipline
Closure
Public letter of reprimand
Cite and fine
Medical education courses
Probation
Revocation
Criminal discipline
Probation
Jail / Prison time
Fines
Administrative vs. Criminal OutcomesAdministrative vs. Criminal Outcomes